JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65

Benzinga · 1d ago
JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $70 to $65.